Close
Enter your
text here

GLP-1

A New Era in Pediatric Obesity Treatment
 A New Era in Pediatric Obesity Treatment 1024 683 Joan Han, MD
By: Joan Han, MD
A hand adjusts the weight measurement on a doctor's scale in a healthcare setting.

For decades, pediatric obesity treatment options were limited. Clinicians relied primarily on lifestyle interventions, with few effective medications available for children and adolescents. Today, however, advances in obesity medicine are transforming care and creating new opportunities to improve long-term health outcomes for young patients. Obesity is increasingly recognized as a complex, chronic disease influenced by…

What Pediatric Endocrinologists Need to Know About Diabetes in the Age of GLP-1s
 What Pediatric Endocrinologists Need to Know About Diabetes in the Age of GLP-1s 1024 683 Erin Gregory
By: Erin Gregory

GLP-1 receptor agonists such as Ozempic (semaglutide) offer new opportunities for managing pediatric diabetes and obesity. These medications target insulin resistance and related comorbidities, but their use raises questions about safety, access and ethical considerations. In the following interview, Leena Mamilly, MD, and Rohan K. Henry, MD, pediatric endocrinology experts at Nationwide Children’s Hospital, explore…

Treating Obesity With GLP-1s — Finding the Way Forward
 Treating Obesity With GLP-1s — Finding the Way Forward 150 150 Abbie Miller
By: Abbie Miller

Using lessons learned from medicating mental and behavioral health conditions, Stephen Cook, MD, offers suggestions about how medications approved for adolescents with obesity should become part of care.   For most of the time in Western medicine, people have treated obesity like a choice — not a disease. Like other conditions now understood to be…